SCHEMBL1330989

SCHEMBL1330989

CC(C)(O)Cn1cc(-c2n[nH]c3cc(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)ccc23)cn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 5/20 0.51
KDR P35968 5/20 0.51
AURKB Q96GD4 4/20 0.51
LCK P06239 3/20 0.51
ROCK1 Q13464 2/20 0.51
AURKA O14965 2/20 0.51
MAP4K4 O95819 2/20 0.51
PDGFRB P09619 2/20 0.51
PDGFRA P16234 2/20 0.51
CDK8 P49336 2/20 0.51
PRKX P51817 2/20 0.51
PIM1 P11309 2/20 0.51
MET P08581 1/20 0.51
CDK5 Q00535 1/20 0.51
MAPK1 P28482 1/20 0.51
FGFR1 P11362 6/20 0.49
DDR2 Q16832 6/20 0.49
KIT P10721 3/20 0.48
FLT3 P36888 3/20 0.48
FYN P06241 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1331406 0.88 FGFR1 (0.58) NTRK1KDRAURKBLCKROCK1
SCHEMBL1330644 0.87 FGFR1 (0.57) NTRK1KDRAURKBLCKROCK1
SCHEMBL1331695 0.85 AURKB (0.61) NTRK1KDRAURKBLCKROCK1
SCHEMBL1330849 0.84 KDR (0.56) NTRK1KDRAURKBLCKROCK1
SCHEMBL1329973 0.83 FGFR1 (0.60) NTRK1KDRAURKBLCKROCK1
SCHEMBL1330605 0.82 NTRK1 (0.53) NTRK1KDRAURKBLCKROCK1
SCHEMBL1331637 0.79 KDR (0.64) NTRK1KDRAURKBLCKROCK1
SCHEMBL1331332 0.79 FGFR1 (0.71) NTRK1KDRAURKBLCKROCK1
SCHEMBL1331350 0.78 GSK3B (0.59) NTRK1KDRAURKBLCKROCK1
SCHEMBL1331471 0.78 NTRK1 (0.54) NTRK1KDRAURKBLCKROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293738-B2 Indazole inhibitors of kinase ABBOTT LABORATORIES (US) 2012-10-23 US disclosed
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE ABBOTT LABORATORIES (US) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281868-A1 INDAZOLE INHIBITORS OF KINASE AURKA, AURKC, AURKB NTRK1 805/4885KDR 11/4885AURKB 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.